go to top

U.S. Error Puts Afghanistan's Counternarcotics Progress at Risk

, Tuesday, Nov. 29, 2011

On Sept. 26, deep inside Taliban-controlled territory in Afghanistan’s Helmand province, Afghan counternarcotics agents backed by their Australian counterparts seized and destroyed $350 million worth of illegal narcotics. The operation set a record for drug seizures in Afghanistan, according to the U.S. Drug Enforcement Administration. Two weeks earlier, the same authorities busted the largest heroin-producing facility found in Afghanistan since 2006, capturing drugs worth $150 million if sold in the U.S. Both operations took millions of dollars from the pockets of insurgents who might otherwise use the money to buy weapons and ultimately mount narco-terrorist attacks inside Afghanistan.

But a grave bureaucratic error by the U.S. government has shut down major anti-drug training programs in Afghanistan, threatening these vital missions and dealing a major blow to Afghan capacity-building. In September, the Pentagon withdrew funding and personnel from the Counternarcotics Training Program in Afghanistan, the Afghan National Customs Academy and the Afghan Advanced Border Management Academy, after it discovered that it had not properly received Congressional authorization to finance the programs. As a result of the oversight, which only recently came to light, all of the programs were disbanded in late-September, around the time of the successful raids in Helmand. Senior U.S. drug enforcement officials described the shutdown as a major setback, effectively undoing three years of progress made in training and gaining the trust of their Afghan counterparts. ...

Want to Read the Rest?
Login or Subscribe Today.
Get unlimited access to must-read news, analysis and opinion from top experts. Subscribe to World Politics Review and you'll receive instant access to 9,000+ articles in the World Politics Review Library, along with new comprehensive analysis every weekday . . . written by leading topic experts.

YES, I want to subscribe now.